drugset / Trial / NCT00983580

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

NCT00983580

Phase 2 Completed 107 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This phase II trial is studying how well giving acetylsalicylic acid together with eflornithine works in treating patients at high risk for colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acetylsalicylic acid and eflornithine may prevent colorectal cancer.

Timeline

Start
2009-08-20
Primary completion
2016-10-07
Completion
2019-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule Oral
Subject Eflornithine Small molecule Oral